Cancer Protein IGF2BP3 Drives Metastasis Through Novel Autophagy Mechanism
New research reveals how IGF2BP3 protein promotes triple-negative breast cancer spread by hijacking cellular recycling processes.
Summary
Researchers discovered that IGF2BP3, a protein highly expressed in triple-negative breast cancer (TNBC), promotes cancer metastasis through a previously unknown mechanism involving autophagy. The protein binds to c-Met mRNA and enhances its translation without affecting mRNA stability, leading to increased autophagy and epithelial-to-mesenchymal transition. This process enables cancer cells to survive in harsh environments and spread to distant organs. The findings reveal IGF2BP3 as a potential therapeutic target for preventing TNBC metastasis, the most aggressive form of breast cancer with limited treatment options.
Detailed Summary
Triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype, lacking estrogen, progesterone, and HER2 receptors, making it resistant to targeted therapies. New research from Nanjing Medical University reveals how IGF2BP3, an RNA-binding protein specifically overexpressed in TNBC, drives cancer metastasis through a novel autophagy-dependent mechanism.
Using multiple TNBC cell lines (MDA-MB-231, BT549, HCC-1806), researchers employed RNA immunoprecipitation sequencing, transmission electron microscopy, and fluorescence imaging to investigate IGF2BP3's role. They discovered that IGF2BP3 knockdown significantly enhanced autophagy markers, increasing LC3-II conversion and reducing P62 levels, while overexpression had opposite effects.
The key breakthrough was identifying c-Met as IGF2BP3's primary target. Through methylated RNA immunoprecipitation sequencing and luciferase assays, researchers found IGF2BP3 binds to m6A methylation sites on both 5' and 3' untranslated regions of c-Met mRNA. Crucially, IGF2BP3 enhanced c-Met protein expression by 2-3 fold without affecting mRNA stability, instead promoting cap-independent translation initiation by recruiting eIF4G2.
In vivo experiments using nude mice demonstrated that IGF2BP3 knockdown reduced lung metastases, while c-Met overexpression rescued this effect. The mechanism operates through the c-Met/PI3K/AKT/mTOR pathway, where IGF2BP3-mediated c-Met upregulation activates autophagy and epithelial-to-mesenchymal transition, enabling cancer cells to survive metabolic stress during metastasis.
These findings establish IGF2BP3 as a critical link between epigenetic modification (m6A) and metabolic adaptation (autophagy) in cancer progression, offering new therapeutic targets for TNBC treatment.
Key Findings
- IGF2BP3 knockdown increased autophagy marker LC3-II by 2-fold and decreased P62 levels by 60% in TNBC cells
- IGF2BP3 enhanced c-Met protein expression by 2-3 fold without affecting mRNA stability (p<0.01)
- IGF2BP3 bound to m6A sites on both 5' and 3' UTRs of c-Met mRNA with 4-fold enrichment vs control
- IGF2BP3 knockdown reduced TNBC cell migration by 70% in wound healing assays (p<0.001)
- In vivo lung metastasis was significantly reduced in IGF2BP3 knockdown mice vs controls
- IGF2BP3 recruited eIF4G2 to promote cap-independent c-Met translation initiation
- The mechanism operated through c-Met/PI3K/AKT/mTOR pathway activation of autophagy-mediated EMT
Methodology
Researchers used multiple TNBC cell lines (MDA-MB-231, BT549, HCC-1806) with lentiviral knockdown/overexpression systems. Key techniques included RNA immunoprecipitation sequencing, methylated RNA immunoprecipitation, transmission electron microscopy, GFP-mCherry-LC3 fluorescence imaging, and co-immunoprecipitation mass spectrometry. In vivo validation used female nude mice (n=6 per group) with tail vein injection of 1.5×10⁶ cells and 4-week follow-up. Statistical analysis employed Student t-tests and one-way ANOVA with p<0.05 significance threshold.
Study Limitations
The study was conducted primarily in cell culture models with limited in vivo validation using only nude mice. The research focused specifically on TNBC cell lines, so generalizability to other cancer types remains unclear. The authors noted that the bidirectional role of autophagy in cancer progression adds complexity to therapeutic targeting. Additionally, the study did not address potential off-target effects of IGF2BP3 inhibition or long-term safety considerations for therapeutic applications.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.